2023
Patent Ductus Arteriosus and Development of Bronchopulmonary Dysplasia-associated Pulmonary Hypertension.
Gentle S, Travers C, Clark M, Carlo W, Ambalavanan N. Patent Ductus Arteriosus and Development of Bronchopulmonary Dysplasia-associated Pulmonary Hypertension. American Journal Of Respiratory And Critical Care Medicine 2023, 207: 921-928. PMID: 36378949, PMCID: PMC10111998, DOI: 10.1164/rccm.202203-0570oc.Peer-Reviewed Original ResearchConceptsBPD-associated pulmonary hypertensionPatent ductus arteriosusDuctus arteriosus patencyPreterm infantsBronchopulmonary dysplasiaPostnatal dayDuctus arteriosusPulmonary hypertensionRespiratory supportModerate to large patent ductus arteriosusBronchopulmonary dysplasia-associated pulmonary hypertensionPreterm infants of gestational ageInfants of gestational ageRetrospective case-control studyEvolving bronchopulmonary dysplasiaExtremely preterm infantsCase-control studyModifiable risk factorsGestational ageDuctal patencyComposite outcomeControl subjectsRisk factorsInfantsPatency
2018
Caffeine controversies
Gentle S, Travers C, Carlo W. Caffeine controversies. Current Opinion In Pediatrics 2018, 30: 177-181. PMID: 29346141, DOI: 10.1097/mop.0000000000000588.Peer-Reviewed Original ResearchConceptsApnea of prematurityBronchopulmonary dysplasiaPreterm infantsEvidence of bronchopulmonary dysplasiaCaffeine usePatent ductus arteriosusRate of motor impairmentCaffeine therapyRate of deathRandomized controlled trialsDuctus arteriosusNeurodevelopmental impairmentTherapy initiationNeonatal careCaffeine groupFollow-upTiming of initiationInfantsPretermCaffeineDoseMotor impairmentRisk reductionImpairmentApnea